Sava Infond d.o.o. Purchases 3,570 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Sava Infond d.o.o. increased its stake in IQVIA Holdings Inc. by 33.3%, acquiring an additional 3,570 shares, bringing its total holdings to 14,290 shares valued at approximately $2.25 million.
• Multiple institutional investors, including Pacer Advisors Inc. and JPMorgan Chase & Co., have significantly expanded their positions in IQVIA this year, indicating strong investor interest.
• The company recently reported earnings of $2.81 EPS, surpassing expectations and projecting earnings growth with FY 2025 guidance of 11.750-12.050 EPS.

Sava Infond d.o.o. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 33.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,290 shares of the medical research company's stock after purchasing an additional 3,570 shares during the quarter. Sava Infond d.o.o.'s holdings in IQVIA were worth $2,252,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in IQV. Pacer Advisors Inc. grew its stake in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after acquiring an additional 854,732 shares during the period. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA during the 1st quarter valued at approximately $77,096,000. Nuveen LLC bought a new position in shares of IQVIA during the 1st quarter valued at approximately $76,328,000. Finally, Platinum Investment Management Ltd. bought a new position in shares of IQVIA during the 2nd quarter valued at approximately $61,585,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Mizuho upped their price target on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial upped their price target on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Weiss Ratings restated a "hold (c)" rating on shares of IQVIA in a research note on Saturday, September 27th. Eighteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $230.32.

IQVIA Stock Up 1.2%

Shares of IQV opened at $206.84 on Friday. The stock has a market capitalization of $35.16 billion, a price-to-earnings ratio of 29.93, a price-to-earnings-growth ratio of 2.24 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.34. The business's 50 day simple moving average is $187.90 and its 200-day simple moving average is $167.69. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.